Blood levels of lignocaine and bupivacaine were measured in children following caudal, subcutaneous and tracheal administration. The highest peak levels were in children under 3 years following tracheal spray but all blood levels were below accepted toxic adult levels for anaesthetised patients. No toxic manifestations were seen.
There is little information regarding the blood levels of various local anaesthetic agents when used in ohildren. Most of the data on blood levels and toxicity currently available has been determined for adult patients or from neonatal studies following delivery where the movher has had local or regional analgesia.
The aim of this study was to determine whether commonly accepted dosages used in children produce blood levels within a safe range. Topical, subcutaneous and caudal epidural administration of two widely used local anaesthetics, lignocaine and bupivacaine, were used to compare peak plasma levels and initial plasma level/time profiles. METHOD (a) Patients studied were having routine elective procedures at the Royal Children's Hospital. Patients aged from 5 days to 15 years of age and were divided into 2 broad groups:
1. Fit, healthy, general surgical patients. The indication for caudal epidural analgesia being those patients undergoing pudendal or lower abdominal surgery. Topical analgesia was given to those patients requiring endotracheal intubation. 2. Bupivacaine hydrochloride 0.5 %, 2 mg/ kg for caudal and subcutaneous administration.
Children

Cc) Sampling and Analysis
Venous samples of 2 ml were taken from a vein in the back of the hand or forearm with a heparinized syringe. Only 1 ml samples were taken in young infants. An initial control sample was followed by sampling at 5, 10, 15, 20, 30, 45, 60 and 90 minutes after local anaesthetic administration. Plasma was separated from the samples and stored for up to 4 weeks at -20°C until analysed specifically for lignocaine or bupivacaine by gas chromatography using a 2% Dcon 75-H-90,000, 2% KOH on Gas Chrome Q column and an FID detector. Full details of the analysis procedure are available elsewhere C Kidd 1978). Samples stored at -20°C for 8 weeks gave identical results to freshly separated plasma.
Cd) Data Analysis
To compare the effect of age on plasma concentration the patients were divided into the following groups: less than 1 year 1-2 years 3-4 years 5-9 years 10+ years RESULTS Table I summarizes the ages, routes of administration and number of patients in each category. Figure 1 presents the spread of results in the 3-5 year group for topical lignocaine, subcutaneous lignocaine and cau.:ial bupivacaine. Figures 2-6 summarize the mean blood levels for each group for the different route of administration and Figure 7 summarizes the peak plasma concentration for each group studied. 
Topical Application to Mucous Membranes Plasma levels as shown in Figure 2 fall into two patterns. Patients older than 3 years of age had a similar response to adults (Chu e/ al. 1975) , with peak levels of about 4 ,ug/ml within 10 minutes of application. A higher peak level was observed in those patients under 3 years of age. In two patients the plasma level exceeded 8 ,ug/ml and in all patients less than I year the peak plasma level occurred earlier -the first sample taken at two minutes was the highest in these patients.
Subcutaneous Administration
In general, the plasma levels were very low following subcutaneous injection into the groin (Figure 3 and 4) . Peak levels in the range 1-2 ,ug/ml lignocaine were obtained at 10-20 minutes after injection and remained fairly constant over the sampling period. Plasma levels following bupivacaine injection rose to 0.5 ,ug/ml over the first 15-20 minutes and remained fairly constant with no significant peak. 
Caudal Administration
The curves plotted in Figures 5 and 6 for plasma levels resulting from caudal injection show similar characteristics to those following subcutaneous administration. Peak levels of 2 ",g/ml were obtained for lignocaine at 10-20 minutes following injection with no significant fall off over the 90 minutes. To simplify comparison of the plasma level data the results have been described as mean plasma level curves for each category. 95% confidence limits were calculated for the 3-5 age group (Figure 1 ) and the spread of results was similar in the other categories. Table 2 summarizes the results of this study and others following topical application of lignocaine to the respiratory tract. It is interesting to note that in the top section of this table containing results of better controlled studies the mean ",g/ml peak plasma level is similar to the mg/kg dose of lignocaine. The lower half of Table 2 summarizes the less well controlled  studies and the Table includes possible reasons for the lack of correlation of the plasma levels and the dose. A linear relationship between epidural lignocaine dose and the resultant peak level has also been demonstrated (['cwino and Vassallo 1976) .
The most striking results from thIs study are those plasma levels reached following topical administration of lignocaine in the under 3 year age group. In some instances these levels reached the potentially toxic range for lignocaine in unanaesthetised adults (5.3 [Lg/ml -Foldes et al. 1960 ) but were below the levels of about 10 [Lg/ml which is considered toxic in anaesthetised adults (8romage and Robson 1961). Venous sampling has been shown to result in a lower peak level than arterial sampling by 0.6 to 0.7 vg/ml (Pclton et al. 1970) . Even considering this difference the levels in our patients did not reach the potential toxic levels and no clinical evidence of toxicity was seen. 20-65% lost to air administration -delayed application >50% 105s to air delayed application 10 4 Some atomizer agent remained in nebulizer hose delayed application 30 t plasma level ,ug/ml of the HCI salt . 4 10-15 mins administration before timing commenced.
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